NCT00072566View on ClinicalTrials.gov

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Primary Peritoneal CarcinomaRecurrent Ovarian CarcinomaStage IV Ovarian Cancer
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Cyclophosphamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

91010

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00072566 - Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter